The regulatory laws in major Asian countries donot permit the early phase trials on account of the high risk involved. Most of the early phase drug development is considered un ethical in the Asian countries if carried out without regulatory permissions. Hence the market growth in Asian countries tends to take a backseat on account of the same.
Most of the early clinical development takes place in the developed markets of the USA and Europe. The Early Phase trials which are then conducted are then projected and conducted in relevant populations and geographical regions (As per protocol, sponsor and regulatory requirements and the results, i. e. endpoints of the trial. Thus most of the outsourced clinical development market comes to the cost effective Asian regions only in the post early phases i.e. phase II onwards.
Veeda Clinical Research is a leading Indian CRO which caters to cost effective bio-equivalence studies for the Global and Indian Pharma industry and early phase development in United Kingdom in a major way.